Your browser doesn't support javascript.
loading
Efficacy and safety of an innovative short-course regimen containing clofazimine for treatment of drug-susceptible tuberculosis: a clinical trial.
Zheng, Xubin; Gui, Xuwei; Yao, Lan; Ma, Jun; He, Yifan; Lou, Hai; Gu, Jin; Ying, Ruoyan; Chen, Liping; Sun, Qin; Liu, Yidian; Ho, Chih-Ming; Lee, Bai-Yu; Clemens, Daniel L; Horwitz, Marcus A; Ding, Xianting; Hao, Xiaohui; Yang, Hua; Sha, Wei.
Afiliación
  • Zheng X; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Gui X; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Yao L; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Ma J; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • He Y; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Lou H; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Gu J; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Ying R; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Chen L; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Sun Q; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Liu Y; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Ho CM; Department of Mechanical and Aerospace Engineering, University of California, Los Angeles, CA, USA.
  • Lee BY; Department of Bioengineering, University of California, Los Angeles, CA, USA.
  • Clemens DL; Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, USA.
  • Horwitz MA; Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, USA.
  • Ding X; Division of Infectious Diseases, Department of Medicine, University of California, Los Angeles, CA, USA.
  • Hao X; Institute for Personalized Medicine, School of Biomedical Engineering, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
  • Yang H; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
  • Sha W; Clinic and Research Centre of Tuberculosis, Shanghai Key Laboratory of Tuberculosis, Shanghai Pulmonary Hospital, Tongji University, Shanghai, People's Republic of China.
Emerg Microbes Infect ; 12(1): 2187247, 2023 Dec.
Article en En | MEDLINE | ID: mdl-36872899
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Clofazimina Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Emerg Microbes Infect Año: 2023 Tipo del documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Tuberculosis / Clofazimina Tipo de estudio: Clinical_trials / Guideline Límite: Humans Idioma: En Revista: Emerg Microbes Infect Año: 2023 Tipo del documento: Article